Category Archives: Global

Ebola Outbreak Raises Ethical Issues

The development of new treatments and preventives to combat the lethal Ebola virus has been slow, marked by caution at public health agencies to approve testing of high-risk compounds, and reluctance of biopharmaceutical companies to invest in a field with limited market potential. All that has changed now, as thousands of people have been sickened […]
Also posted in Regulatory, Safety | Tagged , , | Leave a comment

M&As: Past, Present, and Future

Pharmaceutical Technology’s Faiz Kermani looks at the long history of pharma mergers and finds no sign of the trend slowing down. It was suggested that in one week of April the total value of various rumored deals was of the order of US$100 billion, illustrating how cash-rich major pharmaceutical companies are. Many of the larger […]
Also posted in Deals, Emerging Markets, Europe, Guest Blog, R&D, Strategy | Tagged , , | Leave a comment

New Products Will Force 'Radical Shift' in Hemophilia Drug Market

The hemophilia treatment landscape is to undergo a radical shift away from established short-acting therapies, beginning with the launch of Biogen Idec’s long-acting rFVIII and rFIX products this year, according to research and consulting firm GlobalData. The GlobalData report states that the patient shares of currently marketed short-acting recombinant products will erode considerably by 2022 […]
Posted in Global | Tagged , | Leave a comment

Primary Care Diabetes Prescriptions Cost UK Over £2 Million a Day

Prescriptions to manage diabetes in primary care in the UK cost the NHS an average of £2.2 million ($3.7 m) every day in 2013-14, according to a report from the Health and Social Care Information Centre (HSCIC). The report, Prescribing for Diabetes, also shows the Net Ingredient Cost (NIC)  for managing diabetes was £803.1 million ($1,347 m) in 2013–14. […]
Also posted in Europe, healthcare | Tagged , | Leave a comment

Europe Leads Generic-Drugs Assessment Project

The European Union’s  decentralized procedure is to be used by international regulatory agencies as a model for facilitating generic-drug application assessments, as part of the International Generic Drug Regulations Pilot (IGDRP) project. At the request of a generic-drug company, the EU will share assessment reports in real time with collaborating international regulatory agencies. According to […]
Also posted in Europe | Tagged , , | Leave a comment
  • Categories

  • Meta